-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Industry News] While recently listed companies have disclosed their annual reports, their cash dividends have also attracted the attention of investors
.
Flush data shows that as of April 5, among the 136 A-share listed companies in the pharmaceutical and biological industry that have disclosed their 2021 annual reports, 109 companies plan to distribute cash dividends, with a total cash dividend of over 26.
3 billion yuan
.
The cash dividends of many pharmaceutical companies have exceeded 1 billion yuan.
Judging from the division of labor of these more than 100 companies, there are 58 companies with more than 100 million yuan, including Zhendong Pharmaceutical, Yunnan Baiyao, Daan Gene, WuXi AppTec, and Fosun Pharma.
, Yiqiao Shenzhou, Livzon Group, Huitai Medical and other dividends are particularly generous, and the cash dividends all exceed 1 billion yuan
.
According to Zhendong Pharmaceutical's announcement on March 31, the company's 2021 profit distribution plan is: to distribute cash dividends of 27 yuan (tax included) to all shareholders for every 10 shares, with a total cash dividend of more than 2.
774 billion yuan
.
Yunnan Baiyao announced on the evening of February 25 that it plans to distribute a cash dividend of 39 yuan (tax included) for every 10 shares to all shareholders, with a cash dividend of about 4.
917 billion yuan
.
Daan Gene announced the 2021 annual dividend plan on March 31: Based on 1.
403 billion shares, a cash dividend of 11.
1 yuan (tax included) will be distributed to all shareholders for every 10 shares, with a total cash dividend of 1.
558 billion yuan
.
On March 24, WuXi PharmaTech announced its 2021 annual dividend plan: to distribute cash dividends of 5.
174 yuan (tax included) to all shareholders for every 10 shares, with a total of 1.
529 billion yuan in cash dividends
.
On March 23, Fosun Pharma announced its annual dividend plan for 2021 at the same time as its results were announced: a cash dividend of RMB 5.
6 (tax included) will be distributed to all shareholders for every 10 shares
.
Yiqiao Shenzhou released the 2021 annual equity distribution implementation announcement on March 23.
The company distributed a cash dividend of 100 yuan (including tax, after tax 90 yuan) for every 10 shares, with a total of 680 million yuan in cash dividends
.
At the same time, 9 shares for every 10 shares were transferred to all shareholders with the capital reserve
.
Livzon Group recently announced its 2021 profit distribution plan while publishing its annual report: it plans to distribute a cash dividend of RMB 13.
00 (tax included) to all shareholders of the company for every 10 shares
.
The distribution plan of Huitai Medical in 2021 is: a cash dividend of RMB 10 (tax included) for every 10 shares, no conversion to increase, no bonus shares
.
This dividend is particularly eye-catching.
It is worth mentioning that the total cash dividend of Zhendong Pharmaceutical has exceeded the net profit attributable to shareholders of the parent company in 2021
.
The annual report shows that the company's net profit in 2021 is 2.
617 billion yuan, a year-on-year increase of 898.
92%
.
The company's dividends account for 105.
99% of its net profit in 2021
.
According to the data, Zhendong Pharmaceutical is mainly engaged in the research and development, production and sales of generic drugs and innovative drugs such as tumor, hair, digestion, urology, and heart and brain, as well as the whole industrial chain of traditional Chinese medicinal materials that integrates seedlings, planting, processing, warehousing and decoction pieces
.
For the substantial increase in performance in 2021, the company can attribute it to two aspects: first, from the company's strategic sale of Langdi Pharmaceuticals during the reporting period, resulting in a profit of about 2.
434 billion yuan; second, Dafeixin minoxidil liniment, Shuxue The revenue of major products such as Ning Injection and Xihuang Pills will continue to increase in volume in 2021, driving rapid growth in performance
.
It is understood that Zhendong Pharmaceutical acquired 100% equity of Langdi Pharmaceutical for 2.
646 billion yuan in May 2016 by issuing shares and paying cash
.
In August 2021, Zhendong Pharmaceutical sold 100% of its wholly-owned subsidiary Langdi Pharmaceuticals to Shanghai Fanglang at a price of 5.
8 billion yuan
.
The sale price is 219% of the purchase price
.
Through this sale, the company made a profit of about 2.
434 billion yuan during the reporting period
.
For this sale, Zhendong Pharmaceutical stated that it is mainly to focus on the development of traditional Chinese medicine, innovative drugs, and hair growth medicine, and at the same time greatly reduce the company's book goodwill
.
The 2021 annual report shows that the goodwill of Zhendong Pharmaceutical has dropped from 2.
335 billion yuan in 2020 to 40.
2396 million yuan
.
In addition to Zhendong Pharmaceutical, the total cash dividends of pharmaceutical companies such as Anke Bio and Teyi Pharmaceutical in 2021 will also exceed the net profit attributable to shareholders of the parent company in 2021
.
However, from the perspective of dividend yield, the overall dividend yield of the pharmaceutical and biological industry is not high
.
As of April 5, the dividend yield of Zhendong Pharmaceutical reached 18.
9%, and the dividend yield of 6 companies including Yiqiao Shenzhou, Daan Gene, Jiangzhong Pharmaceutical, and Teyi Pharmaceutical exceeded 3.
5%
.
More than 80% of the remaining companies have a dividend yield of less than 2%
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
.
Flush data shows that as of April 5, among the 136 A-share listed companies in the pharmaceutical and biological industry that have disclosed their 2021 annual reports, 109 companies plan to distribute cash dividends, with a total cash dividend of over 26.
3 billion yuan
.
The cash dividends of many pharmaceutical companies have exceeded 1 billion yuan.
Judging from the division of labor of these more than 100 companies, there are 58 companies with more than 100 million yuan, including Zhendong Pharmaceutical, Yunnan Baiyao, Daan Gene, WuXi AppTec, and Fosun Pharma.
, Yiqiao Shenzhou, Livzon Group, Huitai Medical and other dividends are particularly generous, and the cash dividends all exceed 1 billion yuan
.
According to Zhendong Pharmaceutical's announcement on March 31, the company's 2021 profit distribution plan is: to distribute cash dividends of 27 yuan (tax included) to all shareholders for every 10 shares, with a total cash dividend of more than 2.
774 billion yuan
.
Yunnan Baiyao announced on the evening of February 25 that it plans to distribute a cash dividend of 39 yuan (tax included) for every 10 shares to all shareholders, with a cash dividend of about 4.
917 billion yuan
.
Daan Gene announced the 2021 annual dividend plan on March 31: Based on 1.
403 billion shares, a cash dividend of 11.
1 yuan (tax included) will be distributed to all shareholders for every 10 shares, with a total cash dividend of 1.
558 billion yuan
.
On March 24, WuXi PharmaTech announced its 2021 annual dividend plan: to distribute cash dividends of 5.
174 yuan (tax included) to all shareholders for every 10 shares, with a total of 1.
529 billion yuan in cash dividends
.
On March 23, Fosun Pharma announced its annual dividend plan for 2021 at the same time as its results were announced: a cash dividend of RMB 5.
6 (tax included) will be distributed to all shareholders for every 10 shares
.
Yiqiao Shenzhou released the 2021 annual equity distribution implementation announcement on March 23.
The company distributed a cash dividend of 100 yuan (including tax, after tax 90 yuan) for every 10 shares, with a total of 680 million yuan in cash dividends
.
At the same time, 9 shares for every 10 shares were transferred to all shareholders with the capital reserve
.
Livzon Group recently announced its 2021 profit distribution plan while publishing its annual report: it plans to distribute a cash dividend of RMB 13.
00 (tax included) to all shareholders of the company for every 10 shares
.
The distribution plan of Huitai Medical in 2021 is: a cash dividend of RMB 10 (tax included) for every 10 shares, no conversion to increase, no bonus shares
.
This dividend is particularly eye-catching.
It is worth mentioning that the total cash dividend of Zhendong Pharmaceutical has exceeded the net profit attributable to shareholders of the parent company in 2021
.
The annual report shows that the company's net profit in 2021 is 2.
617 billion yuan, a year-on-year increase of 898.
92%
.
The company's dividends account for 105.
99% of its net profit in 2021
.
According to the data, Zhendong Pharmaceutical is mainly engaged in the research and development, production and sales of generic drugs and innovative drugs such as tumor, hair, digestion, urology, and heart and brain, as well as the whole industrial chain of traditional Chinese medicinal materials that integrates seedlings, planting, processing, warehousing and decoction pieces
.
For the substantial increase in performance in 2021, the company can attribute it to two aspects: first, from the company's strategic sale of Langdi Pharmaceuticals during the reporting period, resulting in a profit of about 2.
434 billion yuan; second, Dafeixin minoxidil liniment, Shuxue The revenue of major products such as Ning Injection and Xihuang Pills will continue to increase in volume in 2021, driving rapid growth in performance
.
It is understood that Zhendong Pharmaceutical acquired 100% equity of Langdi Pharmaceutical for 2.
646 billion yuan in May 2016 by issuing shares and paying cash
.
In August 2021, Zhendong Pharmaceutical sold 100% of its wholly-owned subsidiary Langdi Pharmaceuticals to Shanghai Fanglang at a price of 5.
8 billion yuan
.
The sale price is 219% of the purchase price
.
Through this sale, the company made a profit of about 2.
434 billion yuan during the reporting period
.
For this sale, Zhendong Pharmaceutical stated that it is mainly to focus on the development of traditional Chinese medicine, innovative drugs, and hair growth medicine, and at the same time greatly reduce the company's book goodwill
.
The 2021 annual report shows that the goodwill of Zhendong Pharmaceutical has dropped from 2.
335 billion yuan in 2020 to 40.
2396 million yuan
.
In addition to Zhendong Pharmaceutical, the total cash dividends of pharmaceutical companies such as Anke Bio and Teyi Pharmaceutical in 2021 will also exceed the net profit attributable to shareholders of the parent company in 2021
.
However, from the perspective of dividend yield, the overall dividend yield of the pharmaceutical and biological industry is not high
.
As of April 5, the dividend yield of Zhendong Pharmaceutical reached 18.
9%, and the dividend yield of 6 companies including Yiqiao Shenzhou, Daan Gene, Jiangzhong Pharmaceutical, and Teyi Pharmaceutical exceeded 3.
5%
.
More than 80% of the remaining companies have a dividend yield of less than 2%
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
